Testicular and cutaneous relapse after hematopoietic transplantation in a patient affected with APL
We read with interest the report by Forrest et al 1 concerning an isolated testicular relapse in a patient affected by acute promyelocytic leukemia (APL) after allogeneic bone marrow transplantation, an event that was considered 'very rare'.
However, we recently have encountered a similar case. In May 1997, a Caucasian 41-year-old man received an allogeneic PBPC transplant from his HLA-identical brother for APL in 3rd CR after conditioning with BU-CY in our institution. Graft-versus-host disease prophylaxis was with cyclosporin A plus short course of methotrexate. At the time of transplant APL had been diagnosed 5 years previously on the basis of typical morphology and detection of the PML/RAR-␣ transcript. Previous chemotherapy that the patient had received at diagnosis of leukemia was ara-C plus idarubicin. At first relapse he was treated with alltrans retinoic acid and received a consolidation course with high dose ara-C plus mitoxantrone. Treatment of a subsequent relapse was with idarubicin plus all-trans retinoic acid followed by a consolidation course with etoposide.
The transplant course was uneventful, but 9 months later the patient presented with painless enlargement of both testes and shortly thereafter cutaneous nodules appeared. Testicular and skin biopsy revealed leukemic infiltration at both sites. CAT scan revealed no evidence of deposits in other organs. Bone marrow aspirate and trephine biopsy were consistent with continuing marrow remission, and peripheral blood counts were in the normal range. However, at that time PML/RAR-␣ was again detected in bone marrow cells. The patient was treated with systemic conven-
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This case of extramedullary relapse of acute promyelocytic leukemia (APL) after allogeneic BMT is indeed similar to the one we described. If, as suggested, 1 prior treatment with all-trans retinoic acid (ATRA) predisposes to the development of extramedullary APL, this type of event may be seen more frequently than in the past. Since ATRA is now part of standard therapy, time will tell whether or not this is so.
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tional-dose chemotherapy with etoposide, but had no response. The lesions eventually cleared with whole skin electron-beam irradiation (24 Gy) with a boost dose to the testes. In an attempt to prevent systemic relapse he is now receiving donor leukocyte infusions. The case not only reinforces the concept of the possibility of extramedullary relapse in the testes after allogeneic transplantation for advanced APL but also raises the possibility that this occurrence may be more common than previously thought. It also should be noted that in this patient, as in the case reported by Forrest et al, a radiation-free conditioning regimen was used.
Another case of testicular relapse in an APL patient after allogeneic BMT was reported by Bekassy et al 2 in a paper describing 26 extramedullary relapses and in this case a radiation-free regimen was also used. We therefore agree with Forrest et al that a conditioning regimen utilizing TBI should be considered for transplanting for advanced phase APL.
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